LOS ANGELES, May 02, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate ...

Thinly traded nano cap Ritter Pharmaceuticals (NASDAQ:RTTR) is poised for a significant down move after announcing that a Phase 3 clinical trial evaluating lead candidate RP-G28 for the treatment of ...

Becker’s ASC Review spoke with William Chey, MD, of Ritter Pharmaceuticals’ medical advisory board, about the first treatment for lactose intolerance, the company’s RP-G28. The treatment has not yet ...

LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate ...

Ritter Pharmaceuticals, Inc. has announced positive results from its Phase 2 study of RP-G28, the first-in-class treatment of lactose intolerance. Treatment with RP-G28 was shown to improve digestive ...

Ritter Pharmaceuticals announced that the phase 3 clinical trial of RP-G28 for lactose intolerance did not meet its primary or secondary end points. Ritter Pharmaceuticals announced that the phase 3 ...

RP-G28, a novel non-digestible oligosaccharide designed to stimulate the gut microbiota to metabolize lactose, significantly reduced symptoms in patients with lactose intolerance, according to a press ...

Additional Data Describes Novel Clinical Symptom Assessment Tool Developed in Phase 2b Trial and to be Used in Upcoming Phase 3 Clinical Trial LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) -- Ritter ...

LOS ANGELES, CA--(Marketwired - Aug 18, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to treat ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ritter Pharmaceuticals announced plans for phase 3 ...

In September 2019, the Company announced that its Phase 3 clinical trial of RP-G28 for lactose intolerance (LI), known as “Liberatus,” failed to demonstrate statistical significance in its ...